BTBP(600161)2025-01-20 09:20Financial Performance - Total operating revenue for 2024 reached CNY 603,352.86 million, an increase of 16.47% compared to the previous year[3] - Net profit attributable to shareholders increased by 39.42% year-on-year, amounting to CNY 154,743.19 million[3] - Basic earnings per share rose to CNY 0.78, reflecting a 39.42% increase from CNY 0.56 in the previous year[3] - The weighted average return on equity increased by 2.87 percentage points to 14.80%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,584,794.47 million, up 11.70% from the beginning of the period[3] - The company's equity attributable to shareholders increased to CNY 1,113,697.14 million, a growth of 13.38%[3] - The net asset value per share decreased by 5.52% to CNY 5.63, adjusted for capital reserve conversion[3][4] Plasma Collection - The company collected 2,781 tons of plasma in 2024, a year-on-year increase of 15.15%[5] - The company operates 85 plasma collection centers, including subsidiaries, to enhance plasma collection capacity[5] Report Accuracy - The company emphasizes that there are no uncertainties affecting the accuracy of this performance report[6]